Related MeSH Hierarchy (4)
Diseases [C] » Musculoskeletal Diseases [C05] » Joint Diseases » Arthritis » Arthritis, Rheumatoid
Diseases [C] » Musculoskeletal Diseases [C05] » Rheumatic Diseases » Arthritis, Rheumatoid
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Connective Tissue Diseases » Rheumatic Diseases » Arthritis, Rheumatoid
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Arthritis, Rheumatoid
Description
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. MeSH
Hierarchy View
Subtype Terms (6)
Felty Syndrome
2 approved drugs
Rheumatoid Nodule
2 experimental drugs
Sjogren's Syndrome
109 drugs (46 approved, 63 experimental)
Still's Disease, Adult-Onset
14 drugs (9 approved, 5 experimental)
Approved Indicated Drugs (63)
Phase 3 Indicated Drugs (59)
Phase 1 Indicated Drugs (105)
Other Experimental Indicated Drugs (52)
Organization Involved with Phase 4 Indications (207)
Academic Medical Organization of Southwestern Ontario
Amsterdam Rheumatology and Immunology Center
Arthritis and Pain Associates of PG County
Arthritis and Rheumatic Disease Associates, P.C.
Arthritis & Rheumatism Associates, P.C.
Arthritis Treatment Center, Frederick, Maryland
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
Bangabandhu Sheikh Mujib Medical University
Cantonal Hospital of St. Gallen
Central Hospital of Kanta-Hame
Centre Hospitalier Régional d'Orléans
CHENLIJI Pharmaceutical Company
CHINESE RHEUMATISM DATA CENTER
Chinese SLE Treatment And Research Group
Chinese University of Hong Kong
Fauji Foundation Hospital, Rawalpindi
Feinstein Institute for Medical Research
First People's Hospital of Foshan
Hoosier Cancer Research Network
hospital universitario marques Valdecilla
Japan Biological Agent Study Integrated Consortium
Jawaharlal Institute of Postgraduate Medical Education and Research
Katholieke Universiteit Leuven
King Edward Medical University
Lincoln Medical and Mental Health Center
Mashhad University of Medical Sciences
Medical Benefits Fund Australia Pty Ltd
National Health and Medical Research Council, Australia
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Northumbria Healthcare NHS Foundation Trust
Pakistan Institute of Medical Sciences
People's Liberation Army of China
Postgraduate Institute of Medical Education and Research
Qilu Hospital of Shandong University
Reade Rheumatology Research Institute
Rheumatism Foundation Hospital
Rheumatology Associates of Baltimore, L.L.C.
Second Military Medical University
Shanghai Pharmaceuticals Holding Co., Ltd
Simcere Pharmaceutical Co., Ltd
South-Eastern Norway Regional Health Authority
Spanish Foundation of Rheumatology
Taipei Veteran General hospital
The Arthritis Clinic of Northern Virginia, P.C.
Organization Involved with Phase 3 Indications (118)
All India Institute of Medical Sciences
Arthritis and Rheumatic Disease Specialties
Arthritis & Rheumatic Disease Specialties Research
Arthritis Treatment Center, Maryland
Atención Integral en Reumatología
Centro Médico Privado de Reumatología
Centro Reumatologico Strusberg
China Academy of Chinese Medical Sciences
Coephycient Pharmaceutical Consultancy
Daewon Pharmaceutical Co., Ltd.
Epirus Biopharmaceuticals (Switzerland) GmbH
Hospital of Lithuanian University of Health Sciences
Humanis Klinikum Niederosterreich
Kerckoff clinic, Bad Nauheim, Germany
King Christian X's Rheumatism Hospital, Graasten, Denmark
Low Country Research Center, North Charelston SC
Mochida Pharmaceutical Company, Ltd.
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
National Heart, Lung, and Blood Institute (NHLBI)
Nichi-Iko Pharmaceutical Co., Ltd.
Oklahoma Medical Research Foundation
Orrin M Troum, M.D. and Medical Associates
Pirogov Russian National Research Medical University
QUID Quality in Drugs and Devices Latin American Consulting SRL
Organization Involved with Phase 2 Indications (138)
Advanced Accelerator Applications
Altoona Center for Clinical Research
AmpliPhi Biosciences Corporation
Bilcare Global Clinical Supplies
Camargo Pharmaceutical Services
Coeur d Alene Arthritis Clinic
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
Icahn School of Medicine at Mount Sinai
Maidstone & Tunbridge Wells NHS Trust
Maoxiang Group Jilin Pharmaceutical Co., Ltd.
Molecular Research Center, Inc.
Office of Dietary Supplements (ODS)
Oregon Health and Science University
Pharmaceutical Research Associates, Inc. (PRA)
Rebecca MacDonald Centre for Arthritis
Organization Involved with Phase 1 Indications (59)
Accutest Research Laboratories (I) Pvt. Ltd.
Bio-Kinetic Clinical Applications
National Institutes of Health (NIH)
Orlando Clinical Research Center
Organization Involved with Other Experimental Indications (32)
German Federal Ministry of Education and Research
National Institute of Nutrition and Seafood Research, Norway
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
